Providing Better-Matched Donors for HLA Mismatched Compatible Pairs Through Kidney Paired Donation

Transplantation. 2017 Mar;101(3):642-648. doi: 10.1097/TP.0000000000001196.

Abstract

Background: Participation of compatible pairs (CP) in kidney paired donation (KPD) could be attractive to CPs who have a high degree of HLA mismatch, if the CP recipient will gain a better HLA match. Because KPD programs were not designed to help CP, it is important to define allocation metrics that enable CP to receive a better-matched kidney, without disadvantage to incompatible pairs (ICP).

Methods: Simulations using 46 ICPs and 11 fully HLA-mismatched CPs were undertaken using the Australian KPD matching algorithm. Allocations were preformed adding 1 CP at a time or all 11 CPs at once, and with and without exclusion of unacceptable antigens selected to give a virtual calculated panel-reactive antibody ranging 70% to 80% to improve HLA matching in CP recipients.

Results: On average, most CP recipients could be matched and had a lower eplet mismatch (EpMM) with the matched donor (57 ± 15) than with their own donor (78 ± 19, P < 0.02). However, only recipients who had an EpMM to own donor greater than 65 achieved a significant reduction in the EpMM with the matched donor. The gain in EpMM was larger when CPs were listed with unacceptable antigens. Furthermore, inclusion of 1 CP at a time increased matching in ICP by up to 33%, and inclusion of all 11 CPs at once increased ICP matching by 50%.

Conclusions: Compatible pair participation in KPD can increase match rates in ICP and can provide a better immunological profile in CP recipients who have a high EpMM to their own donor when using allocation based on virtual crossmatch.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ABO Blood-Group System / immunology
  • Algorithms
  • Australia
  • Biomarkers / blood
  • Computer Simulation
  • Donor Selection*
  • Graft Rejection / blood
  • Graft Rejection / immunology
  • Graft Rejection / prevention & control*
  • HLA-A Antigens / immunology*
  • Histocompatibility Testing / methods*
  • Histocompatibility*
  • Humans
  • Isoantibodies / blood
  • Kidney Transplantation / adverse effects
  • Kidney Transplantation / methods*
  • Predictive Value of Tests
  • Risk Assessment
  • Risk Factors
  • Tissue Donors*
  • Treatment Outcome

Substances

  • ABO Blood-Group System
  • Biomarkers
  • HLA-A Antigens
  • Isoantibodies